Hikma Pharmaceuticals (LON:HIK) Share Price Passes Above Two Hundred Day Moving Average – What’s Next?

Hikma Pharmaceuticals PLC (LON:HIK) passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 1,460.77 and traded as high as GBX 1,494. Hikma Pharmaceuticals shares last traded at GBX 1,474.39, with a volume of 508,198 shares changing hands.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Jefferies Financial Group upped their price objective on Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the company a “buy” rating in a report on Tuesday, May 5th. Berenberg Bank reaffirmed a “buy” rating and issued a GBX 1,800 price objective on shares of Hikma Pharmaceuticals in a report on Tuesday, April 28th. Five analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of GBX 2,128.

Hikma Pharmaceuticals Trading Down 0.1%

The company has a debt-to-equity ratio of 63.59, a quick ratio of 1.27 and a current ratio of 1.82. The business has a fifty day simple moving average of GBX 1,365.06 and a 200 day simple moving average of GBX 1,460.88. The stock has a market capitalization of £3.17 billion, a price-to-earnings ratio of 8.15, a price-to-earnings-growth ratio of 2.38 and a beta of 0.64.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.